Evidence map›Paper›PMID 41410160›Full record

ArticleEuropean journal of immunology2025

Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway.

Anne Reversat, Paul T Kennedy, Anni Georghiou, Joseph R Slupsky, Lekh N Dahal

Abstract read
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anne ReversatDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Paul T KennedyDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Anni GeorghiouDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0009-0003-0644-944X
Joseph R SlupskyDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Lekh N DahalDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8390-6593

Funding

Northwest Cancer Research (NWCR), UK
6 · The paper itself

Abstract

The stimulator of interferon genes (STING) pathway plays a pivotal role in innate immunity, acting as a key sensor of cytosolic DNA to initiate type-I Interferon (IFN) and pro-inflammatory cytokine production. This pathway is essential for host defence against bacterial, viral and other pathogenic threats and has emerged as a promising therapeutic target in cancer immunotherapy. However, conventional techniques such as immunoblotting and qPCR are limited in their capacity to study STING pathway activation in complex and heterogeneous biological systems, such as tumour masses or large cell populations. Here, we describe the application of mass cytometry (CyTOF) as a cutting-edge approach to characterize the STING pathway at the sub-population level. Using a high-dimensional panel of metal-labelled antibodies targeting key STING signalling components, we achieved resolution of pathway activation across diverse immune cell populations. This approach promises novel insights into cellular heterogeneity, pathway dynamics and the interplay between STING signalling and other immune pathways and underscores the power of high-dimensional analysis to overcome the limitations of traditional methods to enable a more comprehensive exploration of immune signalling pathways.

Indexed as

Flow CytometryMembrane ProteinsSignal TransductionAnimalsHumansImmunity, InnateInterferon Type ISTING ProteinInterferon Type IMembrane ProteinsSTING1 protein, humanSTING Proteinimmunotherapyinnate immunitymass cytometrySTING

Identifiers

PMID41410160
PMCPMC12712875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.